Abstract
Triptolide is the primary compound isolated from Tripterygium wilfordii, which has been reported to inhibit nucleotide excision repair as well as exhibit anti-inflammatory and antitumor activities. However, the action of triptolide in DNA breaks remains unknown. The present study investigated the effects of triptolide in the induction of DNA breaks and apoptosis in a murine B-cell lymphoma cell line, CH12F3. An MTT assay revealed that X-ray repair cross-complementing protein 1 (XRCC1)<sup>-/-</sup> CH12F3 cells were more sensitive to 6 nM triptolide compared with the wild-type CH12F3 cells, which suggests that low levels of triptolide induce DNA breaks in a manner that is dependent on the XRCC1-mediated repair pathway. Flow cytometric analysis identified that 50 nM triptolide increased the phospho-histone H2AX level, demonstrating that triptolide induces double-strand breaks. Western blot analysis revealed that triptolide up-regulated Rad51 and nuclear proliferating cell nuclear antigen. Annexin V/propidium iodide staining identified that triptolide promoted apoptosis and western blot analysis confirmed that triptolide activated caspase-3-dependent apoptosis. The results of the present study also demonstrated that 5 nM triptolide sensitized CH12F3 lymphoma cells to poly(ADP-ribose) polymerase 1 and phosphoinositide 3-kinase inhibitors, suggesting that triptolide may be a potent antitumor drug for sensitizing lymphoma cells to chemotherapeutic agents.
Introduction
Triptolide, a bioactive compound derived from the "Thunder God Vine" (Tripterygium wilfordii), has long been recognized for its potent anti-inflammatory and antitumor properties. However, its precise molecular mechanism for inducing DNA damage has remained largely unmapped. While known to inhibit certain transcription factors, its role in creating DNA breaks and its potential for synergistic combination therapy in B-cell lymphoma were previously poorly understood. This study aims to clarify how triptolide attacks cancer cell DNA and whether it can be used to sensitize tumors to existing targeted therapies.
Methods
The researchers utilized the murine B-cell lymphoma cell line CH12F3 as a primary model. To identify which DNA repair pathways triptolide interferes with, they compared wild-type cells against specialized knockout variants:
- XRCC1⁻/⁻: Deficient in base excision repair (BER) and single-strand break repair.
- Ligase IV⁻/⁻: Deficient in non-homologous end-joining (NHEJ), a primary pathway for double-strand break repair.
Experimental techniques included MTT assays for cell viability, flow cytometry to detect γH2AX (a biomarker for double-strand breaks), and Western blotting to observe changes in repair proteins like Rad51 and PCNA, as well as apoptotic markers like Caspase-3.
Results
Differential Sensitivity and the XRCC1 Pathway
The study found that cells lacking XRCC1 were significantly more sensitive to triptolide than wild-type or Ligase IV-deficient cells. At a low dose of 6 nM, the survival of XRCC1⁻/⁻ cells dropped to approximately 40%, while wild-type cells remained largely unaffected. This indicates that triptolide-induced damage primarily targets pathways managed by XRCC1, such as single-strand breaks.
Induction of Double-Strand Breaks and Compensatory Response
While low doses target XRCC1-dependent pathways, higher doses (50 nM) clearly induce double-strand breaks (DSBs), confirmed by a sharp increase in γH2AX levels via flow cytometry. Interestingly, the cells attempted to mount a compensatory response to this damage. Western blot analysis revealed a significant, dose-dependent upregulation of repair proteins Rad51 and PCNA.
Therapeutic Sensitization
The most clinically relevant finding was that a sub-lethal dose of triptolide (5 nM) acted as a powerful sensitizer. When combined with PARP1 (ME0328) or PI3K (BKM120) inhibitors, triptolide dramatically increased the kill rate of lymphoma cells compared to using the inhibitors alone. By intentionally damaging the DNA and then blocking the cell's ability to repair that damage, the combination therapy achieved high efficacy at lower individual drug dosages.
Discussion
These results demonstrate that triptolide induces DNA breaks that trigger caspase-dependent apoptosis. The discovery that triptolide sensitizes B-cell lymphoma to PARP1 and PI3K inhibitors suggests a promising new strategy for combination therapy. By lowering the required dose of toxic chemotherapeutics through sensitization, clinicians may eventually be able to reduce side effects for patients. Future research should focus on in vivo animal models to confirm these synergistic effects in a whole-body system.
Summary updated